Literature DB >> 15860351

AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells.

Jijiang Zhu1, James L Abbruzzese, Julie Izzo, Walter N Hittelman, Donghui Li.   

Abstract

To test the hypothesis that AURKA amplification contributes to pancreatic tumorigenesis by increasing centrosome abnormality and chromosome instability, the current study explored the associations between AURKA amplification, chromosome instability, centrosome abnormality, and the expression of several important proteins that are involved in cell proliferation (Ki-67), cell cycle regulation (p53, p16), and apoptosis (survivin) in 12 human pancreatic carcinoma cell lines. Using fluorescence in situ hybridization (FISH), we observed that 5 of the 12 cell lines had an AURKA amplification index (AI) (percentage of cells with more than three signals) >60%. Both the AURKA AI and the average number of signals per cell (ANSPC) were significantly associated with the copy number of chromosome 9 but not chromosome 17. The AURKA ANSPC was positively associated with the percentage of cells with the centrosome abnormality. Furthermore, centrosome abnormality was significantly associated with the frequency of cells with abnormal nuclei and abnormal mitotic figures, but no direct association was detected between the frequency of centrosome abnormalities and chromosome instabilities. The AURKA AI was also associated with a lower expression of Ki-67, a higher expression of survivin, and the lack of expression of p16. These associations support our hypothesis that AURKA amplification contributes to pancreatic carcinogenesis by increasing chromosome instability and centrosome abnormality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860351     DOI: 10.1016/j.cancergencyto.2004.09.008

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  22 in total

1.  MAD1 (mitotic arrest deficiency 1) is a candidate for a tumor suppressor gene in human stomach.

Authors:  Mitsuhiko Osaki; Toshiaki Inoue; Shigeyuki Yamaguchi; Aiko Inaba; Naruo Tokuyasu; Kuan-Teh Jeang; Mitsuo Oshimura; Hisao Ito
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Authors:  Guillermo Garcia-Manero; Raoul Tibes; Tapan Kadia; Hagop Kantarjian; Martha Arellano; Emily A Knight; Hao Xiong; Qin Qin; Wijith Munasinghe; Lisa Roberts-Rapp; Peter Ansell; Daniel H Albert; Brian Oliver; Mark D McKee; Justin L Ricker; Hanna Jean Khoury
Journal:  Invest New Drugs       Date:  2015-05-02       Impact factor: 3.850

4.  Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma.

Authors:  Karuna Mittal; Angela Ogden; Michelle D Reid; Padmashree C G Rida; Sooryanarayana Varambally; Ritu Aneja
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

Authors:  Yuanhua Cheng; Wei Cui; Quan Chen; Chen-Ho Tung; Mingjuan Ji; Fushi Zhang
Journal:  J Comput Aided Mol Des       Date:  2011-01-11       Impact factor: 3.686

6.  Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe.

Authors:  Angela Mathison; Ann Salmonson; Mckenna Missfeldt; Jennifer Bintz; Monique Williams; Sarah Kossak; Asha Nair; Thiago M de Assuncao; Trace Christensen; Navtej Buttar; Juan Iovanna; Robert Huebert; Gwen Lomberk
Journal:  Mol Cancer Res       Date:  2017-04-25       Impact factor: 5.852

7.  Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression.

Authors:  Zhengyu Fang; Yi Xiong; Jiana Li; Li Liu; Manhui Li; Chao Zhang; Wei Zhang; Jun Wan
Journal:  Med Oncol       Date:  2010-06-29       Impact factor: 3.064

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

9.  Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome.

Authors:  Fergus J Couch; Xianshu Wang; William R Bamlet; Mariza de Andrade; Gloria M Petersen; Robert R McWilliams
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

10.  A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer.

Authors:  Satoko Yamamoto; Mutsuko Yamamoto-Ibusuki; Yutaka Yamamoto; Saori Fujiwara; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2013-04-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.